Targeting the Root Cause: Senolytics and the Paradigm Shift in Fibrosis Treatment

Introduction

Senescent cells are cells that have irreversibly stopped dividing. Once thought to be merely "dormant," recent research has revealed that these cells actively secrete a cocktail of inflammatory factors known as the SASP (Senescence-Associated Secretory Phenotype), which drives fibrosis in surrounding tissues.

Drugs that selectively eliminate these "zombie cells"—called Senolytics—represent a paradigm shift in treating fibrotic diseases.

The Mechanism: How Senescent Cells Drive Fibrosis

The SASP Factor

Senescent cells secrete various factors that alter the tissue microenvironment:

SASP Factor	Function	Contribution to Fibrosis
IL-6, IL-1β	Inflammatory cytokines	Maintains chronic inflammation
TGF-β	Pro-fibrotic factor	Activates myofibroblasts
MMP-2, MMP-9	Matrix metalloproteinases	ECM remodeling
PAI-1	Plasminogen activator inhibitor	Inhibits fibrinolysis

Organ-Specific Impact

IPF (Idiopathic Pulmonary Fibrosis)

• Senescence of alveolar epithelial cells (especially Type II) drives disease progression
• Accumulation of p16^INK4a^-positive cells confirmed in human IPF lung tissue
• Senescent fibroblasts acquire apoptosis resistance

MASH (Metabolic Dysfunction-Associated Steatohepatitis)

• Senescence of hepatocytes and hepatic stellate cells
• p21-positive senescent cells correlate with liver fibrosis progression
• Lipid metabolism abnormalities induce senescence via DNA damage

Senolytics: Mechanism of Action and Key Candidates

Mechanism of Action

Senescent cells depend heavily on survival signals (anti-apoptotic pathways: SCAPs). Senolytics selectively induce apoptosis in senescent cells by inhibiting these pathways.

Key Target Pathways:

• BCL-2/BCL-xL (anti-apoptotic proteins)
• p53/p21 pathway
• PI3K/AKT pathway
• Tyrosine kinases

Key Drug Candidates in Development

Compound	Mechanism	Development Stage	Target Indication
Dasatinib + Quercetin (D+Q)	Tyrosine kinase + flavonoid	Phase 2	IPF, Diabetic nephropathy
UBX1325 (Unity)	BCL-xL inhibitor	Phase 2	Diabetic macular edema
Navitoclax (ABT-263)	BCL-2/BCL-xL inhibitor	Phase 1/2	Myelofibrosis
Fisetin	Natural flavonoid	Phase 2	Long COVID

Unity Biotechnology Updates

Unity Biotechnology is a pioneer in senescent cell research, with a focus on ophthalmology. UBX1325 showed promising results in Phase 2 trials for diabetic macular edema. However, extending applications to broader fibrotic diseases requires optimization of tissue-specific delivery.

Challenges and Future Directions

Current Challenges

1. Off-target toxicity: BCL-2/BCL-xL inhibitors may cause thrombocytopenia
2. Dosing regimen: Optimization of intermittent dosing (hit-and-run therapy) needed
3. Biomarkers: Establishing non-invasive methods to measure senescent cell burden

Research Directions

• Second-generation Senolytics: Development of more selective BCL-xL inhibitors
• Senomorphics: Approaches that suppress SASP without eliminating senescent cells
• CAR-T therapy: Cell therapy targeting senescent cell surface markers (e.g., uPAR)

Summary

Senescent cells are a "hidden target" in fibrotic diseases, and Senolytics offer an innovative approach to address them. While ophthalmology and hematological diseases are currently leading, applications to IPF and MASH are anticipated. Evaluating senescent cells in preclinical models requires specialized techniques such as β-galactosidase staining and p16/p21 immunostaining, making collaboration with experienced partners key to success.

---

References

1. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536.
2. Schafer MJ, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8:14532.
3. Ogrodnik M, et al. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8:15691.
4. Unity Biotechnology Pipeline (https://unitybiotechnology.com/pipeline/)